Celltrion Healthcare Co., Ltd. (091990)
Market Closed
15 Dec, 06:30
KRX SM KOSDAQ Primary KRX SM ₩
75,900. 00
-4,500
-5.597%
₩
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
1,138.83 Eps
₩ 80,400
Previous Close Want to track 091990 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
091990 closed Friday lower at ₩75,900, a decrease of -5.597% from Thursday's close, completing a monthly increase of 0% or ₩75,900. Over the past 12 months, 091990 stock gained 0%.
091990 is not paying dividends to its shareholders.
The last earnings report, released on May 10, 2024, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -41.99%, based on the last three reports.
Celltrion Healthcare Co., Ltd. has completed 4 stock splits, with the recent split occurring on Dec 28, 2022.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on KOSDAQ (KRW).
091990 Chart
Celltrion Healthcare Co., Ltd. (091990) FAQ
What is the stock price today?
The current price is ₩75,900.00.
On which exchange is it traded?
Celltrion Healthcare Co., Ltd. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 091990.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Celltrion Healthcare Co., Ltd. ever had a stock split?
Celltrion Healthcare Co., Ltd. had 4 splits and the recent split was on Dec 28, 2022.
Celltrion Healthcare Co., Ltd. Profile
| - Industry | - Sector | Joon Serk Seo CEO | KRX SM Exchange | KR7091990002 ISIN |
| KR Country | - Employees | 28 Dec 2022 Last Dividend | 28 Dec 2022 Last Split | - IPO Date |
Overview
Celltrion Healthcare Co., Ltd., headquartered in Incheon, South Korea, specializes in the manufacture, processing, and global distribution of biosimilar and biological medicines. Originally established in 1999 under the name Nexol, Inc., the company underwent a rebranding to its current name in March 2009. It is dedicated to providing advanced therapeutic solutions, targeting a variety of serious diseases, to patients worldwide. As of December 28, 2023, Celltrion Healthcare functions as a subsidiary of Celltrion, Inc., emphasizing its substantial role within the larger biopharmaceutical landscape.
Products and Services
Celltrion Healthcare Co., Ltd. offers a range of biosimilar medicines catering to multiple therapeutic areas:
- Remsima: A monoclonal antibody biosimilar designed for the treatment of various autoimmune diseases. It is indicated for conditions such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, both adult and children's Crohn's disease, psoriasis, and psoriatic arthritis. Remsima represents a pioneering effort in making biologic treatments more accessible to patients suffering from autoimmune disorders.
- Truxima: This biosimilar targets lymphoma and chronic lymphocytic leukemia, as well as autoimmune diseases like Wegener's granulomatosis and microscopic polyangiitis, in addition to rheumatoid arthritis. Truxima highlights Celltrion Healthcare’s ability to provide vital medicines for both cancer and autoimmune conditions, expanding treatment options for patients worldwide.
- Herzuma: Approved for the treatment of metastatic breast cancer, early breast cancer, and metastatic gastric cancer, Herzuma embodies Celltrion Healthcare’s commitment to fighting cancer. By providing a biosimilar option for these conditions, Herzuma helps to improve access to essential cancer therapies.
- Remsima SC: An innovative subcutaneous formulation of Remsima for the treatment of rheumatoid arthritis, this product showcases Celltrion Healthcare’s dedication to improving patient convenience and treatment adherence through advanced drug delivery systems.
Contact Information
Address: Office Building: 19, Incheon, South Korea
Phone: 82 850 6400
Website: https://www.celltrionhealthcare.com
